Tech Company Financing Transactions
Syndax Pharmaceuticals Funding Round
Syndax Pharmaceuticals closed a $9 million funding round on 2/3/2010. Investors included Domain Associates and MPM Capital.
Transaction Overview
Company Name
Announced On
2/3/2010
Transaction Type
Venture Equity
Amount
$9,000,000
Round
Undisclosed
Investors
Domain Associates (Dennis Podlesak)
MPM Capital (Kim Kamdar)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
400 Totten Pond Road 110
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is a Waltham, MA-based, oncology-focused biotechnology company that is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Briggs Morrison
Chief Financial Officer
Allan Shaw
Chief Technical Officer
Peter Ordentlich
President
Michael Metzger
VP - Operations
Jeannette Hasapidis
Browse more venture capital transactions:
Prev: 2/3/2010: Single Touch Interactive venture capital transaction
Next: 2/3/2010: Gigamon venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs